ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Samir K BrahmachariSubscribe to Samir K Brahmachari

Economic Impact of Technology Interventions--Streptokinase

More than 20 lakh patients of ischaemic heart disease-led myocardial infarction can benefit from a life-saving clot-buster drug in India. At the turn of the century, its availability in India was poor and no domestic production existed until the first Council of Scientific and Industrial Research licensee began production in 2001-02. Its price was less than half that of the drug made by a multinational company, the major supplier in the market at that time. Its supply increased to 1,20,000 doses in 2011 after other producers entered the market. Prices dropped by more than 50%. The economic impact of streptokinase technologies, or the value that would be lost if the licensee's streptokinase did not exist, is about `580 crore for the patients.

Thrombolytic Treatment for Myocardial Infarction

All authors were formerly at Council of Scientific and Industrial Research HQ, New Delhi. This study looks at the available life-saving treatments for heart attacks and ischaemic heart diseases administered in India, focusing on streptokinase and finding that it is the life-saving clot-buster for the majority of patients. This brings to light that the surgical intervention of angioplasty is more of an income-biased treatment. Public-funded research and development of indigenous streptokinase has directly enabled access to treatment, especially for economically challenged patients.
Back to Top